These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 3170346)

  • 21. In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
    Antimicrob Agents Chemother; 2008 Feb; 52(2):761-6. PubMed ID: 18070958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial susceptibility of anaerobic and aerobic bacteria isolated from patients with mixed infections in Nicaragua.
    Cáceres M; Carrera E; Palma A; Berrios G; Weintraub A; Nord CE
    Rev Esp Quimioter; 1999 Dec; 12(4):332-9. PubMed ID: 10855012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative in-vitro activity of ceftazidime (GR-20263) and other beta-lactamase stable cephalosporins against anaerobic bacteria.
    Chow AW; Bartlett KH
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():91-5. PubMed ID: 19802974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In-vitro activity of BRL-36650, a novel beta-lactamase-stable penicillin, against multiply resistant gram-negative organisms.
    Verbist L
    J Antimicrob Chemother; 1986 Sep; 18(3):351-8. PubMed ID: 3095299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-vitro activity of ceftazidime compared with other beta-lactam antibiotics.
    Clarke AM; Zemcov SJ
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():57-62. PubMed ID: 19810169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The activity of metal compounds against aerobic and anaerobic bacteria.
    Chin N; Neu HC
    Diagn Microbiol Infect Dis; 1992 Aug; 15(6):549-52. PubMed ID: 1424509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin.
    Neu HC; Chin NX; Jules K; Labthavikul P
    J Antimicrob Chemother; 1986 Apr; 17(4):441-52. PubMed ID: 3486862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The activity of cefpirome and ten other antibacterial agents against 2858 clinical isolates collected from 20 centres.
    Reeves DS; Bywater MJ; Holt HA
    J Antimicrob Chemother; 1993 Mar; 31(3):345-62. PubMed ID: 8486569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.
    Goldstein EJ; Citron DM; Warren YA; Tyrrell KL; Merriam CV; Fernandez HT
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2875-9. PubMed ID: 16870792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The study of drug resistance in aerobic and anaerobic bacterial flora to selected antibacterial drugs].
    Michalska W; Chylak J; Pietkiewicz K
    Med Dosw Mikrobiol; 1996; 48(1-2):61-70. PubMed ID: 8926770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
    Jones ME
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sch 34343: in-vitro antibacterial activity and susceptibility to beta-lactamases.
    Shannon K; King A; Phillips I
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():15-23. PubMed ID: 3897169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
    Pillar CM; Aranza MK; Shah D; Sahm DF
    J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
    J Antimicrob Chemother; 2002 Sep; 50(3):411-20. PubMed ID: 12205068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibacterial effect of imipenem in vitro against important aerobic and anaerobic strains isolated from clinical specimens.
    Klietmann W; Focht J; Nösner K
    Chemioterapia; 1987 Aug; 6(4):243-50. PubMed ID: 3477332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents.
    Citron DM; Goldstein EJ; Merriam CV; Lipsky BA; Abramson MA
    J Clin Microbiol; 2007 Sep; 45(9):2819-28. PubMed ID: 17609322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests.
    Fuchs PC; Barry AL; Brown SD
    J Antimicrob Chemother; 1999 May; 43(5):703-6. PubMed ID: 10382893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.